Nathalie Cartier-Lacave, PhD, Cell and Gene Therapy for Neurodegenerative Diseases, INSERM ICM (Institute for Brain and Spine). Dr Cartier-Lacave is a research director at INSERM, where she leads the group “Biotherapies of neurodegenerative diseases”. Dr Cartier-Lacave is president of the European Society of Gene and Cell Therapy (ESGCT).
Ronald G. Crystal, MD, Professor and Chairman, Department of Genetic Medicine, Weill Cornell Medicine. Dr. Crystal performed pioneering seminal work on adenoviral and AAV vectors, which accelerated the translation of gene therapy from the research laboratory to the clinic. His current research focus includes optimizing viral gene transfer vectors for in vivo gene therapy for hereditary and acquired brain disorders. Dr. Ronald Crystal is a paid consultant for Lysogene. He has also conducted lectures, with full content control, supported by Lysogene.
Steven Gray, PhD, Associate Professor, Department of Pediatrics, UT Southwestern Medical Center. Dr. Gray’s core expertise is in AAV gene therapy vector engineering, followed by optimizing approaches to deliver a gene to the nervous system and preclinical studies to apply AAV vectors toward the development of treatments for neurological diseases.
Chester B. Whitley, PhD, MD, University of Minnesota Medical School, Minneapolis. Dr Whitley is a key opinion leader in the field of lysosomal Storage diseases, founding Course Director for WORLDSymposium, and Principal Investigator for the global Lysosomal Disease Network. He accomplished the first clinical trial of gene therapy for a mucopolysaccharidosis disease (1998-9).